Skip to main content
. 2020 Sep 17;11(9):770. doi: 10.1038/s41419-020-02974-0

Fig. 2. Oral administration of GP2 induces pro-glucagon expression and GLP-1 secretion in the intestine.

Fig. 2

a, b Immunoblot (a) for pro-glucagon in RIPA lysis extracts from the ilea of mice treated with or without GP2 for 2 weeks and quantification (b) (n = 5). c–f Plasma concentrations of active GLP-1 (c) and insulin (e) in HFD-fed mice in response to oral of 2.0 g/kg glucose with or without GP2 treatment (200 mg/kg/d, bid) for 2 weeks (n = 5–6); area under the curve of active GLP-1 level (d) and insulin level (f) in 15 min after glucose challenge in (c) and (e). Results are shown as the mean ± s.e.m., *P < 0.05, **P < 0.01 compared with vehicle.